Cipher Pharmaceuticals has appointed John MacInnis as vice president, portfolio development and licensing. Mr. MacInnis will be responsible for identifying and evaluating pipeline products and technologies, and pursuing strategic alliances and partnerships for the company's drugs in targeted markets.
   
Mr. MacInnis has experience in the life sciences industry with expertise in large global pharmaceutical, private equity and portfolio management consulting. Most recently, he was vice president, business development at Kromite, a consulting firm that offers strategic support to life science companies, including technical risk assessment and benchmarking, forecasting, licensing support, portfolio and resource optimization and strategic planning. He held the position of executive vice president, business development at DRI Capital, where he was responsible for the identification and evaluation of life science royalty financing opportunities. Previously, he served as director, disease area strategy within Novartis Global Marketing (Basel), and executive director, CNS Franchise within the strategic marketing group at Johnson and Johnson.
   
"We are very pleased to welcome John to the team," said Larry Andrews, president and chief executive officer of Cipher Pharmaceuticals. "His global new product and business development knowledge, private equity experience and complementary skill set will be highly beneficial in our pursuit of new product opportunities and additional partnerships for our current late-stage portfolio."

News from our sister sites